Adjuvant endocrine therapy for premenopausal hormone receptor-positive breast cancer: Much done, more to do

ONCOLOGY

Volumn 23, Issue 1, 2009, Pages

  Higgins, Michaela J ^a   Wolff, Antonio C ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GONADORELIN AGONIST; GOSERELIN; METHOTREXATE; TAMOXIFEN; TRIPTORELIN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; AMENORRHEA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EARLY CANCER; EARLY MENOPAUSE; HUMAN; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; OVULATION INHIBITION; PREMENOPAUSE; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; RISK REDUCTION;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GOSERELIN; HUMANS; OVARY; PREMENOPAUSE; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 61449101760     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351:1451-1467, 1998.
2. Giordano SH, Hortobagyi GN: Time to remove the subspecialty blinders: Breast cancer does not exist in isolation. J Natl Cancer Inst 100:230-231, 2008.
3. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005.
4. LHRH-agonists in Early Breast Cancer Overview Group: Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: A meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369:1711-1723, 2007.
5. Ovarian ablation or suppression in pre-menopausal early breast cancer. Results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. J Natl Cancer Inst 99:516-525, 2007.
6. Petrek JA, Naughton MJ, Case LD, et al: Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: A prospective study. J Clin Oncol 24:1045-1051, 2006.
7. Colleoni M, Rotmensz N, Peruzzotti G, et al: Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol 17: 1497-1503, 2006.
8. Baum M, Hackshaw A, Houghton J, et al: Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study. Eur J Cancer 42:895-904, 2006.
9. Jannuzzo MG, Di Salle E, Spinelli R, et al: Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. Breast Cancer Res Treat. March 11, 2008.
10. Gnant MB, Mlineritsch B, Schippinger W, et al: Adjuvant ovarian suppression combined with tamoxifen or anastrazole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12 (abstract LBA4). J Clin Oncol 26(15S):6s, 2008.
11. Smith IE, Dowsett M, Yap YS, et al: Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorhoea: Caution and suggested guidelines. J Clin Oncol 24:2444-2447, 2006.
12. Thürlimann B, Price KN, Gelber RD, et al: Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat. Feb 8, 2008.
13. Goldhirsch A, Wood WC, Gelber RD, et al: Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133-1144, 2007.
14. NCCN practice guidelines in oncology, v.2.2008. Available at www.nccn.org. Accessed Dec 16, 2008.